药物发现
恶病质
癌症
药品
细胞外小泡
计算生物学
药物开发
转化研究
鉴定(生物学)
系统药理学
疾病
精密医学
医学
生物信息学
个性化医疗
癌症治疗
转化医学
胞外囊泡
生物标志物发现
药物重新定位
免疫系统
药理学
癌症治疗
多学科方法
临床试验
靶向治疗
信号转导
癌症研究
肿瘤科
临床前研究
免疫疗法
癌细胞系
功效
药物反应
神经科学
作者
Ryosuke Sato,Markus S. Anker,Jochen Springer,Stephan von Haehling
标识
DOI:10.1080/17460441.2025.2562020
摘要
INTRODUCTION: Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting the urgent need for developing novel experimental models. AREA COVERED: This review covers recent advancements in preclinical models of CC, highlighting their implications for drug discovery and therapeutic development. The literature search was conducted in PubMed up to April 2025. EXPERT OPINION: CC remains clinically challenging and requires improved translational research and therapeutic strategies. Improved preclinical models, such as personalized patient-derived xenograft models incorporating patient-specific immune profiles and microbiota, hold promise for precision medicine. Identification of standardized extracellular vesicle (EV) derived biomarkers and effective targeting of EV signaling pathways are critical research directions. In addition, clinical validation of appetite regulators such as glucagon-like peptide-1 and growth differentiation factor-15, along with comprehensive approaches integrating diet, exercise, and targeted pharmacological interventions, will be pivotal. Finally, multidisciplinary collaboration is essential to translate these findings into meaningful therapies that will ultimately improve patient prognosis and quality of life.
科研通智能强力驱动
Strongly Powered by AbleSci AI